Dr. Alexi Grom (video) discusses his presentation from ACR 2024, on the 80% success rate of an anti-IFN gamma mAb (emapalumab) when used in 39 Stills disease patients complicated by life-threatening macrophage activation syndrome. https://t.co/kIPmsVXkCP https://t.co/ib9pKEpZ4L